2023
DOI: 10.1039/d3md00030c
|View full text |Cite
|
Sign up to set email alerts
|

Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents

Abstract: The unique features of ferrocene and the need for development of targeted anticancer drugs, inspired the design, synthesis and biological evaluation of ferrocenyl modified tyrosine kinase inhibitors by replacing the...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 48 publications
0
0
0
Order By: Relevance